StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report published on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Up 4.6 %
NASDAQ GLMD opened at $0.34 on Wednesday. Galmed Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $5.47. The stock has a market capitalization of $1.69 million, a PE ratio of -0.14 and a beta of 0.80. The firm has a 50 day moving average of $0.38 and a two-hundred day moving average of $0.38.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last posted its quarterly earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) EPS for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
See Also
- Five stocks we like better than Galmed Pharmaceuticals
- ESG Stocks, What Investors Should Know
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- 3 Monster Growth Stocks to Buy Now
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
